Skip to main content
Premium Trial:

Request an Annual Quote

Visby Medical Wins $12.3M BARDA Contract for Coronavirus, Flu Combo Test

NEW YORK — The US Department of Health and Human Services said on Tuesday that Visby Medical has been awarded a Biomedical Advanced Research and Development Authority contract worth $12.3 million to develop a handheld diagnostic for SARS-CoV-2 and influenza.

According to the HHS, the PCR-based test will be a version of Visby's single-use, fully integrated COVID-19 test, which provides results within 30 minutes and received Emergency Use Authorization in September, multiplexed to include the influenza A and B viruses.

While the SARS-CoV-2 test uses respiratory specimens collected by a healthcare provider or self-collected in a healthcare setting, the new test will be designed for both point-of-care and at-home use as an over-the-counter product, the HHS said.

San Jose, California-based Visby, which was awarded $19 million from the National Institutes of Health last year to develop a single-use gonorrhea test, said that the BARDA contract could be extended to run for a total of 38 months with up to $48.7 million in funding. The company is expected to first seek FDA EUA for the multiplex test, followed by a submission for 510(k) clearance.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.